Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Rapport Therapeutics, Inc. ( (RAPP) ) has provided an announcement.
On January 7, 2026, Rapport Therapeutics announced that the U.S. FDA has cleared its lead candidate RAP-219 to advance into Phase 3 registrational trials for focal onset seizures, prompting the company to move the program’s start forward to the second quarter of 2026 and to open a long-term safety study for prior trial participants. Leveraging strong Phase 2a data and physician market research that point to a potential multi-billion-dollar U.S. opportunity in epilepsy, Rapport is expanding RAP-219 development into primary generalized tonic-clonic seizures with a Phase 3 trial slated for the first half of 2027, while continuing a Phase 2 study in bipolar mania and progressing a long-acting injectable formulation and other pipeline assets. At the same time, the FDA has lifted its clinical hold on a RAP-219 trial in diabetic peripheral neuropathic pain, but the company is deferring further spending on that indication to prioritize its α6β4 chronic pain and migraine program, and management says its $513 million cash balance at the end of the third quarter should fund operations into the second half of 2029, supporting a dense slate of clinical milestones in 2026 and beyond.
The most recent analyst rating on (RAPP) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Rapport Therapeutics, Inc. stock, see the RAPP Stock Forecast page.
Spark’s Take on RAPP Stock
According to Spark, TipRanks’ AI Analyst, RAPP is a Neutral.
The score is primarily held back by pre-revenue fundamentals with widening losses and increasing cash burn, despite a strong, low-debt balance sheet. Technicals are supportive (uptrend with positive momentum), but valuation is constrained by negative earnings and no dividend yield data.
To see Spark’s full report on RAPP stock, click here.
More about Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing small-molecule precision medicines for neurological and psychiatric disorders. Built on proprietary receptor associated protein (RAP) technology, the company aims to overcome limitations of conventional neurology drug discovery and is anchored by an epilepsy portfolio targeting focal onset seizures and primary generalized tonic-clonic seizures, alongside programs in bipolar mania, chronic pain, migraine, and hearing/vestibular disorders.
Average Trading Volume: 395,466
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.31B
See more data about RAPP stock on TipRanks’ Stock Analysis page.